RELAPSING MULTIPLE SCLEROSIS

This study follows 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI, a medication given by infusion. Researchers want to see how well it works and what side effects occur in everyday medical practice, not just in a controlled trial. Participants must not h…

This study tests a modified dosing schedule of ublituximab, a drug that targets certain immune cells, in 800 people with relapsing multiple sclerosis (MS). The goal is to see if the new regimen reduces brain lesions (spots of inflammation) better than current approaches. Particip…

This study tests whether CYB704, a proposed biosimilar to the approved drug Ocrevus, works just as well for people with relapsing multiple sclerosis (MS). About 175 adults with relapsing MS will receive either CYB704 or Ocrevus, and researchers will compare how the drug moves thr…

This study follows 800 adults with relapsing multiple sclerosis in Germany to see how long they continue their prescribed injectable or oral treatments. Researchers will collect data from medical records and questionnaires over up to four years. The goal is to understand real-wor…

This study tests whether people with relapsing multiple sclerosis can safely switch from the infusion ocrelizumab to the experimental pill remibrutinib. About 360 adults aged 40-70 will be randomly assigned to either switch or stay on ocrelizumab. The goal is to see if remibrutin…

This study compares a stem cell transplant (AHSCT) with the best standard treatments for people whose relapsing multiple sclerosis (MS) is not controlled by usual therapies. About 156 adults aged 18 to 55 will be randomly assigned to one of the two approaches and followed for 6 y…

This early-stage study tests an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis whose disease has worsened even while on strong treatments. The goal is to check if YTB323 is safe and can control the disease. Participants receive a sing…

This study tests the drug ocrelizumab in 60 Chinese adults with two types of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see how well it controls relapses and reduces immune cells linked to MS. Participants receive the drug by infusion, and re…

This study looks at whether people with stable relapsing multiple sclerosis (MS) can safely switch from a strong infusion therapy (anti-CD20) to a daily pill (ozanimod). The goal is to see if the pill can keep the disease under control with fewer serious infections. About 100 adu…

This study tests an experimental drug called fenebrutinib in 12 children and teens (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions, and if it is safe. Participants can choose to continue …

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. Researchers will collect milk samples from 16 breastfeeding women who already take BRIUMVI for relapsing MS. The goal is to understand drug exposure for nursing infants, not to test a new t…